Routine indexes for cirrhosis and significant fibrosis detection in patients with compensated chronic hepatitis B

Area of Science:

• Hepatology
• Biomarker Discovery
• Diagnostic Accuracy

Background:

• Existing fibrosis indices like FIB-4 and APRI have limited validation in chronic hepatitis B (CHB).
• Accurate non-invasive assessment of liver fibrosis is crucial for CHB management.
• There is a need for validated, cost-effective tools for fibrosis staging in CHB.

Purpose of the Study:

• To validate existing fibrosis indices (FIB-4, APRI) in CHB patients.
• To develop and validate novel, accurate non-invasive biomarkers for liver fibrosis and cirrhosis in CHB.
• To assess the clinical utility of new indices in resource-limited settings.

Main Methods:

• Analysis of 1438 treatment-naïve CHB patients.
• Development of two novel non-invasive indices: HeBCI for cirrhosis and HeBFI for significant fibrosis.
• Validation of index performance using Area Under the Receiver Operating Characteristic Curves (AUROCs) and accuracy metrics.

Main Results:

• HeBCI demonstrated superior AUROCs (0.841 model, 0.779 validation) for cirrhosis detection compared to FIB-4 and APRI.
• HeBFI showed higher AUROCs (0.781 model, 0.776 validation) for significant fibrosis detection than FIB-4 and APRI.
• HeBCI achieved 86% accuracy for cirrhosis, and HeBFI achieved 76.6% accuracy for significant fibrosis.

Conclusions:

• The novel HeBCI and HeBFI indices show high accuracy in detecting cirrhosis and significant fibrosis in CHB patients.
• These indices are economical and convenient, suitable for outpatient use.
• HeBCI and HeBFI can significantly reduce the reliance on liver biopsy, particularly in resource-limited healthcare settings.